Company intelligence / Profile preview
Threshold Pharmaceuticals
South San Francisco, California, United Statesthresholdpharm.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Threshold Pharmaceuticals developed tumor-targeted therapies with a primary focus on hypoxia-targeted small molecules. Its lead drug, evofosfamide (TH‑302), failed two pivotal Phase III trials but continued in early-stage combination studies. The company also developed TH‑3424, a prodrug targeting AKR1C3-expressing cancers, which was acquired by OBI Pharma. In August 2017, Threshold merged with Molecular Templates and ceased independent operations.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeSmall molecule prodrugImaging agentBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Merck KGaA/Merck Serono ($550M co-development/commercialization deal for TH–302/evofosfamide)OBI Pharma acquired rights to develop OBI–3424/TH–3424 for AKR1C3-expressing cancers in Asia-Pacific region before the merger closed.Eleison Pharmaceuticals had an agreement related to another asset as of October 2009.Longitude Capital led $20M financing concurrent with the reverse merger; other investors included CAM Capital and Perceptive Advisors.
Beyond the preview
Go deeper on Threshold Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Threshold Pharmaceuticals.